News Desk — May 18, 2018 at 12:09 am — Updated: May 18, 2018 at 12:09 am

GSK bets on lift from new lung drugs ahead of Advair’s last gasp


LONDON (Reuters) – GlaxoSmithKline is putting more marketing muscle behind its new lung drugs and is looking for a sales boost as top respiratory experts gather to analyse clinical trials data at a meeting in San Diego this weekend.

Leave A Comment Using Facebook (Website Comment Form Below)

Use the form below to post a comment via facebook

Leave a Reply

68 queries in 1.013 seconds.